Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.

被引：0

作者：

Sonpavde, Guru P.

Galsky, Matt D.

Wright, Phoebe

Hepp, Zsolt

Chang, Nancy N.

Willmon, Candice

Sesterhenn, Steven

Liu, Yutong

Morgans, Alicia K.

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Mt Sinai, Tisch Canc Inst, New York, NY USA

[3] Seagen Inc, Bothell, WA USA

[4] Dendreon Pharmaceut LLC, Seattle, WA USA

[5] Seattle Genet, Bothell, WA USA

[6] Astellas Pharma Inc, Northbrook, IL USA

[7] Genesis Res, Hoboken, NJ USA

[8] Dana Farber Canc Inst, Boston, MA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4565

引用

页数：1